Skip to content
    VRTX
    Earnings call· Mar 2025(Q1 FY25)

    VERTEX PHARMACEUTICALS INC / MA Q1 FY25 earnings call VRTX

    May 5, 2025 Source

    Executive summary

    Vertex Pharmaceuticals Q1 FY25 — Strong Launch Momentum and Pipeline Advancement

    Vertex Pharmaceuticals delivered a strong Q1 FY25, marked by continued revenue growth and significant progress across its diversified portfolio. The company is executing on multiple launches, including ALYFTREK and JOURNAVX, while advancing a robust pipeline with five programs in pivotal development. Management remains focused on expanding patient access and driving innovation, despite some isolated ex-U.S. revenue headwinds and a temporary pause in one early-stage CF program.

    Highlights

    5

    • Total revenue grew 3% year-over-year to $2.77 billion in Q1 FY25.

    • U.S. revenue growth was 9% year-over-year, driven by demand, pricing, and ALYFTREK launch.

    • Approximately 90 patients have had their first cell collections for CASGEVY, with over 65 authorized treatment centers activated.

    • JOURNAVX, a novel non-opioid for acute pain, has seen over 25,000 prescriptions filled as of April 25, with 94 million lives having covered access.

    • Full-year 2025 total revenue guidance raised to $11.85 billion to $12 billion, representing 8% growth at the midpoint.

    Concerns

    3

    • Ex-U.S. revenue declined 5% year-on-year in Q1 FY25, primarily due to a $100 million impact from an illegal copy product in Russia.

    • VX-522 (Next-Gen CFTR regimen) Phase I/II study temporarily paused to assess a tolerability issue.

    • Non-GAAP operating income decreased to $1.18 billion in Q1 FY25 from $1.34 billion in Q1 FY24 due to increased operating expenses and lower interest income.

    Guidance & targets

    11
    CategoryTargetConfidence
    Full-year 2025 Total Revenue
    $11.85 billion to $12 billion
    high materiality
    High
    Full-year 2025 Combined Non-GAAP R&D, Acquired IPR&D and SG&A Expenses
    $4.9 billion to $5 billion
    medium materiality
    High
    Full-year 2025 Non-GAAP Effective Tax Rate
    20.5% to 21.5%
    low materiality
    High
    ALYFTREK European Commission Approval
    Expected in H2 2025
    medium materiality
    High
    VX-828 (Next-Gen CFTR regimen) Study Initiation
    Initiate study in patients with CF before the end of this year
    medium materiality
    High
    VX-993 Acute Pain Post Bunionectomy Trial Results
    Report results in the second half of this year
    medium materiality
    High
    Zimislecel (T1D) Pivotal Study Enrollment and Dosing
    Complete enrollment and dosing this quarter
    high materiality
    High
    Pove (IgAN) Interim Analysis and Filing
    Interim analysis after 36 weeks of treatment; support filing in H1 2026 for potential accelerated approval in U.S.
    high materiality
    High
    Pove (Membranous Nephropathy) Pivotal Study Initiation
    Initiate a single Phase II/III adaptive study in H2 2025
    medium materiality
    High
    Inaxaplin (AMKD) Interim Analysis and Filing
    Interim analysis after 48 weeks of treatment; poised to file for potential accelerated approval in U.S.
    high materiality
    High
    VX-407 (ADPKD) Phase II Proof-of-Concept Study Initiation
    Initiate this study in the second half of this year
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    U.S. CF Revenue
    Growth driven by ongoing patient demand, higher net realized pricing, and the early launch of ALYFTREK.
    		—9%——
    Ex-U.S. CF Revenue
    Decline due to increased channel inventory in Q1 2024 from Russia shipments and a negative impact from an illegal copy product in Russia in Q1 2025. Excluding Russia, ex-U.S. CF revenue growth would have been low single digits.
    		—-5%——

    Operational metrics

    22
    Total Revenue
    $2.77B3% YoY growth
    Q1 FY25

    Continuing momentum from 2024 with strong performance across the board.

    CASGEVY Revenue
    $14M
    Q1 FY25

    Included in Q1 total revenue, reflecting continued ramp-up as more patients are treated.

    Collaboration Revenue
    $10M
    Q1 FY25

    Included in Q1 total revenue.

    Combined Non-GAAP R&D, Acquired IPR&D and SG&A Expenses
    $1.23B21% increase vs Q1 FY24
    Q1 FY25

    Increase due to rapid advancement of broad pipeline and build-out of commercial capabilities in pain.

    Non-GAAP Acquired IPR&D Expenses
    $20Mvs $77M in Q1 FY24
    Q1 FY25

    Part of combined operating expenses.

    Non-GAAP Operating Income
    $1.18Bvs $1.34B in Q1 FY24
    Q1 FY25

    Primarily due to increased operating expenses and lower interest income.

    Non-GAAP Effective Tax Rate
    18.8%
    Q1 FY25

    Q1 tax rate.

    Non-GAAP Earnings Per Share
    $4.06vs $4.76 in Q1 FY24
    Q1 FY25

    Primarily due to increased operating expenses and lower interest income.

    Cash and Investments Balance
    $11.4B
    Q1 FY25 end

    After deploying $425 million to repurchase shares.

    Share Repurchases
    $425M
    Q1 FY25

    Part of cash deployment priorities.

    CASGEVY Authorized Treatment Centers (ATCs)
    65+
    Q1 FY25

    Nearing the global activation goal, contributing to accelerating uptake.

    CASGEVY Patient Cell Collections
    90
    Q1 FY25

    Patients have begun the treatment journey. More than twice this number have been referred by physicians.

    CASGEVY Patients Completing Treatment
    8
    Q1 FY25

    Patients received infusions of CASGEVY edited cells in Q1.

    JOURNAVX Prescriptions Filled
    25,000
    As of April 25

    An important indicator of launch progress and unmet need in moderate to severe acute pain.

    JOURNAVX Covered Lives
    94M
    As of May 1

    Across commercial and government payers, with rapid progress in securing access.

    JOURNAVX Commercial Payer Agreement
    22M
    Recent

    Formal coverage agreement reached, included in the 94M total covered lives.

    JOURNAVX State Medicaid Plans with Unrestricted Access
    10
    Current

    Providing unrestricted access with low co-pays.

    JOURNAVX Hospital P&T Committee Reviews
    1/3
    Current

    Many have initiated P&T reviews, some already added to formulary.

    JOURNAVX Average Prescription Duration
    14 days
    Current

    Consistent with typical acute pain treatment.

    Russia Revenue Impact
    $100M
    Q1 FY25

    Negative impact from an illegal copy product, fully included in full-year guidance.

    Pove Subcutaneous Auto-injector Program
    —
    Ongoing

    Program to support the launch of Pove with a subcutaneous auto-injector for monthly at-home administration is well underway.

    VX-407 Phase II Study Design
    —
    H2 FY25 initiation

    Designed to evaluate efficacy of VX-407 in ADPKD.

    Industry KPIs

    7
    MetricValueDetails
    Launch access metrics94Mlives
    Pipeline read out calendarMultiple programs
    Product franchise net sales—
    Regulatory approvals filingsMultiple approvals/opinions
    Prescription volume new starts25,000prescriptions
    Collaboration milestone royalty revenue$10MUSD
    Cumulative patients uptake since launch90patients

    Product announcements

    3
    ProductTypeDetails
    ALYFTREKlaunch
    JOURNAVXlaunch
    KAFTRIO / TRIKAFTAexpansion

    Deals & partnerships

    1
    Alpine Immune SciencesAcquisition of Alpine Immune Sciences

    Approaching the 1-year anniversary of the acquisition, which brought Povetacicept into the pipeline.

    Risks & headwinds

    3
    Illegal copy product impactQ1 FY25 and Full Year FY25

    $100M in Q1 FY25; $200M for full year FY25

    Mitigation: Impact is isolated to Russia and fully included in current guidance.

    VX-522 tolerability issueOngoing

    Study temporarily paused

    Mitigation: Assessing the issue; will provide updates when more information is available, maintaining study integrity.

    Tariff impactOngoing

    Immaterial impact from current tariffs

    Mitigation: Low exposure to China, geographically diverse supply chain, vast majority of IP in U.S./U.K. Outlook subject to change given dynamic nature of tariff situation, including potential for sector-specific tariffs.

    What to watch in Q2 FY25

    5

    VX-993 Acute Pain Results

    H2 FY25
    CurrentPhase II study completed this quarter
    TargetReported results in H2 2025

    Why it matters

    This will provide data on a potentially more potent NaV1.8 inhibitor, offering another option or improved efficacy over JOURNAVX.

    Next, I'm very pleased to share that the study of oral VX-993, another NaV1.8 inhibitor in acute pain post bunionectomy is on track to complete this quarter, and we expect to report results from this trial in the second half of this year.

    Q&A highlights

    8

    What is the feedback on sweat chloride as a biomarker for ALYFTREK, and what drives switches from TRIKAFTA? Also, an update on JOURNAVX chronic pain indications and study designs.

    Sweat chloride is not routinely used in practice, but ALYFTREK's appeal is a combination of non-inferiority to TRIKAFTA, improved CFTR function (sweat chloride), additional 31 mutations covered, and once-daily dosing. For JOURNAVX chronic pain, the end of Phase II meeting with FDA is on track for summer, with innovative study designs.

    “I would say it's really the sum of the parts, Geoff. So it's firstly, the fact that it's demonstrated in large, long, robust clinical trials that it's noninferior to TRIKAFTA, which, as we all know, sets a very high bar in terms of FEV1 and then it is the improvements in CFTR function that people have the potential to access as measured by sweat chloride then reinforcing that improved potential efficacy.”

    asked by Geoffrey Meacham · answered by Stuart Arbuckle

    2 min read5 chapters

    Detailed Narrative

    01

    Commercial Diversification and Launch Momentum

    Vertex is actively diversifying its commercial portfolio with the recent U.S. approvals and launches of ALYFTREK for cystic fibrosis and JOURNAVX for acute pain. ALYFTREK, the fifth CF medicine, has gained MHRA approval in the U.K. and a positive CHMP opinion in the EU, with expected European Commission approval in H2 2025. JOURNAVX, the first oral non-opioid for moderate to severe acute pain in over two decades, has seen rapid retail pharmacy stocking and progress in payer discussions, with 94 million lives having covered access.

    02

    CASGEVY Rollout and Patient Access

    The global rollout of CASGEVY, the gene-edited therapy for sickle cell disease and beta-thalassemia, is progressing as expected, with increasing authorized treatment center (ATC) activations and patient initiations. Over 65 ATCs are now active, nearing the goal of 75 globally. Approximately 90 patients have begun the treatment journey with cell collections, and 8 patients completed treatment in Q1. Reimbursement access has been secured in the U.S. (commercial and Medicaid via CMMI demonstration project), U.K., Denmark, Austria, Luxembourg, Bahrain, Saudi Arabia, and parts of UAE.

    03

    Advancing Late-Stage Pipeline

    Vertex has four programs currently in pivotal development, soon to be five. Suzetrigine in diabetic peripheral neuropathy, Zimislecel in type 1 diabetes, Inaxaplin in APOL-1 mediated kidney disease, and Pove in IgA nephropathy. Three of these Phase III programs are on track to complete enrollment or interim analysis cohorts this year, setting up potential filings in 2026. The company is also initiating a fifth pivotal program for Pove in primary membranous nephropathy in H2 2025.

    04

    Next-Generation CF and T1D Programs

    The Next-Gen (NG 3.0) CFTR regimen, with VX-828 as its backbone, is on track to initiate a patient study by year-end, aiming to achieve normal CFTR function for most patients. However, the Phase I/II study of VX-522 for patients not benefiting from CFTR modulators has been temporarily paused due to a tolerability issue. In type 1 diabetes, Zimislecel's pivotal study is expected to complete enrollment and dosing this quarter, targeting global regulatory submissions in 2026 for severe T1D patients. The VX-264 cells + device program has returned to the research stage.

    05

    Kidney Portfolio Expansion

    The kidney portfolio now includes clinical-stage programs in four renal diseases: IgA nephropathy (IgAN), APOL-1 mediated kidney disease (AMKD), membranous nephropathy, and autosomal dominant polycystic kidney disease (ADPKD). Pove (Povetacicept) has completed enrollment for its IgAN interim analysis cohort and will advance to pivotal development in membranous nephropathy. Inaxaplin for AMKD is on track for interim analysis enrollment this year and has initiated the Amplified study for AMKD patients with comorbidities. VX-407 for ADPKD is set to initiate a Phase II proof-of-concept study in H2 2025.

    AI-generated summary of the company’s earnings call. Not investment advice.